PRP vs HA for Hip OA: Level I/II Meta-Analysis
Belk JW · Arthroscopy (2022)
DOI: 10.1016/j.arthro.2021.11.005This meta-analysis pooled 6 Level I and II RCTs comparing PRP to HA for hip OA, totaling 408 patients. Despite analyzing multiple outcome measures (WOMAC, VAS, Harris Hip Score), no significant differences were found between PRP and HA for any measure. A subanalysis restricted to LP-PRP studies also showed no advantage. This is the definitive meta-analysis establishing that PRP does not outperform HA for hip OA.
Clinical Relevance
Clinicians should not extrapolate positive knee OA PRP data to the hip. For hip OA, PRP and HA appear equivalent, and the cost-benefit analysis likely favors HA given PRP's higher preparation cost. Future hip studies should explore higher concentrations or different delivery methods.
Key Takeaways
- No significant PRP vs HA difference for any outcome (WOMAC, VAS, HHS)
- LP-PRP subanalysis also negative
- 6 RCTs, 408 patients (adequate pooled sample)
- Definitive evidence that hip OA responds differently from knee OA to PRP
- Cannot recommend PRP over HA for hip OA based on current evidence
Key Findings
NO significant PRP vs HA differences. LP-PRP subanalysis also negative. Unlike knee, PRP does NOT outperform HA in hip.
Clinical Context
Study Design
Meta-Analysis
Condition
Hip Osteoarthritis
Sample Size
408 patients
Follow-up
12 months
Control Group
Hyaluronic Acid
Primary Outcome
WOMAC, VAS, HHS
PRP Protocol & Intervention
Preparation System
Various
Leukocyte Status
Mixed (LP-PRP subanalysis done)